TEL AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP ) (TASE: APOP ), a developer of stem cells isolation technology, announced today that the Company will ring The Nasdaq Stock Market Opening Bell at the Nasdaq MarketSite in Times Square on Friday, February 24, 2017. The bell ringing ceremony will commemorate Cellect’s initial listing on the Nasdaq Stock Market, which occurred in the second half of 2016.
“We are honored to celebrate last year’s listing of our ADSs on the Nasdaq Stock Market,” said Cellect’s Chairman, Mr. Nuriel Chirich Kasbian. “Cellect is at a transformative stage of our corporate evolution, and we believe that being a Nasdaq listed company allows us to benefit from the strong appreciation for life sciences companies listed on Nasdaq that investors have historically shown.”
“We are grateful to Nasdaq for inviting us to participate in the opening bell ceremonies,” said Dr. Shai Yarkoni, Cellect’s Chief Executive Officer. “We are proud of our innovative technology in a field that has the potential to transform medicine. We are focused on creating long-term shareholder value, and we are confident that our anticipated future sole listing on NASDAQ is an important step toward accomplishing this objective.”
About Cellect Biotechnology Ltd.
Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: APOP ) (NASDAQ: APOPW ) (TASE: APOP ). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications.
The Company’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell related treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.
Forward-Looking Statements This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect’s innovative technology is in a field that has the potential to transform medicine, that Cellect’s anticipated future sole listing on Nasdaq is an important step towards creating long-term shareholder value, that Cellect has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications and that Cellect’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stems cell related treatments and procedures. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.'s final prospectus dated July 29, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov and in the Company’s period filings with the SEC and the Tel-Aviv Stock Exchange.
Contact Cellect Biotechnology Ltd. Eyal Leibovitz, Chief Financial Officer www.cellectbio.com + 972-9-974-1444 LifeSci Advisors Bob Yedid, Managing Director 646-597-6989 bob@lifesciadvisors.com
